Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06253117 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
A Phase 2 study of Recurrent Acute Pancreatitis, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT06253117: Recruiting Phase 2 study of Recurrent Acute Pancreatitis, sponsored by University of Alabama at Birmingham.
NCT06253117 is a Phase 2 study of Recurrent Acute Pancreatitis that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 60 participants, below the 370-participant average among 5 other Recurrent Acute Pancreatitis trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06253117, a Phase 2 study of Recurrent Acute Pancreatitis, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in patients with recurrent acute pancreatitis.
Primary Outcome
Development of anticipated or un-anticipated serious adverse events (class 3-4)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pirfenidone
Study Locations (2)
Alabama
- UAB - Birmingham
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-06-27 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
What NCT06253117 shows while recruiting
NCT06253117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 370-participant average among 5 other Recurrent Acute Pancreatitis trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Recurrent Acute Pancreatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06253117 reports a single indexed study location in Alabama, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06253117 about?
NCT06253117 is a clinical study titled "Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.". This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in patients with recurrent acute pancreatitis.
What is the current status of trial NCT06253117?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-06-27. Estimated completion is 2028-09-01.
What conditions does trial NCT06253117 study?
This clinical trial studies the following conditions: Recurrent Acute Pancreatitis.
What interventions are being tested in trial NCT06253117?
The interventions under investigation include: Placebo (DRUG), Pirfenidone (DRUG).
Who is sponsoring clinical trial NCT06253117?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06253117 being conducted?
This trial has 2 study locations across Alabama, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Acute Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis
RECRUITING · Phase 2
-
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
RECRUITING
-
Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis
RECRUITING · Early Phase 1
-
Soy Tomato Juice to Improve Outcomes in Pancreatitis
RECRUITING · Phase 1
-
THE Malabsorption Blood Test Trial Will Help Determine THE Benefits OF Pancreatic Enzyme Replacement Therapy IN Patients With Mild TO Moderate Exocrine Pancreatic Insufficiency.
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI